Business Context and Reporting Period
This Form 8-K filing by CHF Solutions, Inc. (trading symbol: CHFS) reports on events occurring on January 16, 2021. The filing details a significant leadership transition within the company, specifically the appointment of a new Chief Executive Officer and President and the restructuring of the role of the former CEO.
Key Financial Metrics
This filing is a current report regarding executive appointments and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes
- Executive Leadership Change: Nestor Jaramillo, Jr. was appointed as Chief Executive Officer and President, effective January 16, 2021. He previously served as Chief Operating Officer and President since June 2020.
- Role Transition for Former CEO: John L. Erb, who served as Chairman, CEO, and President since November 2015, will continue as Chairman of the Board. He transitioned to a part-time employee role (20 hours/week) for a six-month period beginning January 16, 2021.
- Board Expansion: The Board of Directors increased its size from six to seven members, with Mr. Jaramillo appointed as a Class I Director.
Compensation, Outlook, and Risks
Compensatory Arrangements
Nestor Jaramillo, Jr. (New CEO):
- Base Salary: $385,000 annually.
- Performance Bonus: Up to 55% of annual base salary.
- Equity Grant: Option to purchase 12,750 shares granted January 22, 2021, with a 25% cliff vesting on the first anniversary and monthly vesting thereafter over four years.
- Future Equity: Opportunity for an option to purchase shares equal to 2.4% of outstanding stock prior to January 31, 2022.
- Severance: In the event of termination without cause or for "good reason," the agreement provides one times annual base salary, 12 months of medical coverage, continued equity vesting for 12 months, and a pro-rated bonus.
John L. Erb (Chairman/Former CEO):
- Base Salary: $225,000 annualized for the six-month employment period.
- Performance Bonus: Up to $56,250 based on capital markets relations, medical society relations, and transition success.
- Equity Grant: Option to purchase 33,125 shares granted January 22, 2021, with 50% vesting on the first anniversary and monthly vesting thereafter over two years.
Outlook and Risks
The filing does not provide specific financial guidance or outlook for the company's future performance. The primary risk disclosed relates to the execution of the leadership transition and the potential financial obligations associated with executive severance packages under specific termination scenarios.
Investor Verification Checklist
- Verify the exact vesting schedules and exercise prices for the stock options granted to Mr. Jaramillo and Mr. Erb on January 22, 2021.
- Review the full text of the Executive Employment Agreements (Exhibits 10.1 and 10.2) to understand the specific definitions of "cause," "good reason," and "disability."
- Confirm the timeline for the 2.4% equity award opportunity for Mr. Jaramillo, contingent on Board approval.
- Monitor the company's subsequent filings for the first financial results under the new CEO's leadership.